Laurus Labs [LAURUSLABS] Reports Robust Q4 FY24: Net Profit Jumps 19%, Full-Year Performance Soars
Laurus Labs [LAURUSLABS] posted strong financial results for Q4 FY24, with consolidated net profit surging 19% year-on-year to ₹279 crore. The pharmaceutical major also announced an interim dividend of ₹1.20 per share, capping off a remarkable fiscal year.
Leading Indian pharmaceutical company Laurus Labs [LAURUSLABS] has delivered an impressive financial performance for the fourth quarter of fiscal year 2024. The company reported a significant 19% year-on-year increase in its consolidated net profit, reaching ₹279 crore for the quarter ending March 31, 2024.
The pharmaceutical giant's revenue from operations also saw a healthy uptick, rising by 5% year-on-year to touch ₹1,812 crore during the same period. This consistent growth underscores the company's robust operational strategies and market positioning.
Looking at the full fiscal year 2024, Laurus Labs [LAURUSLABS] demonstrated exceptional growth, with its net profit soaring by an astounding 148% to ₹889 crore. This substantial leap in profitability was primarily fueled by outstanding contributions from its Contract Development and Manufacturing Organisation (CDMO) and Generics divisions, highlighting the diversification and strength of its business segments.
In addition to its strong financial outcomes, the company also rewarded its shareholders by announcing an interim dividend of ₹1.20 per equity share, reflecting confidence in its sustained performance and future outlook.
Laurus Labs continues to solidify its position in the global pharmaceutical landscape, driven by its focus on innovation, strategic partnerships, and a strong product pipeline across various therapeutic areas. Investors will be keenly watching how these growth drivers translate into further value creation in the upcoming fiscal year.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions. StockTips.in is not a SEBI-registered investment advisor.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions. StockTips.in is not a SEBI-registered investment advisor.